MDMA Statement on Device Tax Repeal and User Fee Language in Budget Deal
Thursday, December 12, 2013
Washington, D.C. – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement today regarding the inclusion of language in the proposed budget deal identifying medical device tax repeal as a priority and addressing the impact of sequestration on FDA user fees:
"MDMA applauds the continuing bipartisan support for putting an end to the medical device tax. With each passing day, this onerous policy impedes innovation, thwarts patient care and destroys jobs. We have much more work to do, but MDMA and medical technology innovators will work tirelessly with all stakeholders to achieve this bipartisan goal.
"In addition, it is crucial that FDA has access to all industry provided user fees so that it can provide a more reasonable and predictable regulatory framework. Sequestration of these privately paid user fees was an unfortunate consequence that needs to be fully addressed to help ensure America’s medical technology industry can continue to be the global leader.”